Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PTCT
stocks logo

PTCT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
244.00M
+14.46%
-0.374
-55.95%
194.19M
-83.49%
-0.570
-105.68%
213.16M
+19.17%
-0.387
-53.36%
Estimates Revision
The market is revising No Change the revenue expectations for PTC Therapeutics, Inc. (PTCT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 35.96%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+35.96%
In Past 3 Month
Wall Street analysts forecast PTCT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 76.18 USD with a low forecast of 50.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast PTCT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 76.18 USD with a low forecast of 50.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 77.850
sliders
Low
50.00
Averages
76.18
High
118.00
Current: 77.850
sliders
Low
50.00
Averages
76.18
High
118.00
Goldman Sachs
NULL -> Sell
downgrade
$44 -> $50
2025-11-06
Reason
Goldman Sachs
Price Target
$44 -> $50
2025-11-06
downgrade
NULL -> Sell
Reason
Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares.
Goldman Sachs
Sell
maintain
$44 -> $50
2025-11-05
Reason
Goldman Sachs
Price Target
$44 -> $50
2025-11-05
maintain
Sell
Reason
Goldman Sachs raised the firm's price target on PTC Therapeutics to $50 from $44 and keeps a Sell rating on the shares. PTC Therapeutics reported stronger-than-expected Q3 results driven by robust early Sephience sales and solid performance from the legacy Duchenne muscular dystrophy franchise, the analyst tells investors in a research note. Sephience's launch showed encouraging momentum with broad COE engagement and favorable early payer dynamics, though DMD revenue continued to decline sequentially. While early uptake supports confidence in Sephience's trajectory, U.S. sales targets above $1B appear ambitious, and attention now turns to ongoing launch progress, the upcoming votoplam FDA update, and pipeline developments at December's R&D day, Goldman says.
TD Cowen
Joseph Thome
Hold
maintain
$50 -> $63
2025-11-05
Reason
TD Cowen
Joseph Thome
Price Target
$50 -> $63
2025-11-05
maintain
Hold
Reason
TD Cowen analyst Joseph Thome raised the firm's price target on PTC Therapeutics to $63 from $50 and keeps a Hold rating on the shares. The firm said they posted a solid topline beat where nitial Sephience sales of $19.2MM beat the $4MM consensus, and surpassed the higher end of investor expectations.
RBC Capital
Outperform
maintain
$70 -> $82
2025-11-05
Reason
RBC Capital
Price Target
$70 -> $82
2025-11-05
maintain
Outperform
Reason
RBC Capital raised the firm's price target on PTC Therapeutics to $82 from $70 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company's Sephience launch appears to be off to an excellent start, likely surpassing the growing expectations into the quarter, and with signals supporting good near/medium-term durability, the analyst tells investors in a research note.
Citi
Neutral
maintain
$50 -> $75
2025-11-05
Reason
Citi
Price Target
$50 -> $75
2025-11-05
maintain
Neutral
Reason
Citi raised the firm's price target on PTC Therapeutics to $75 from $50 and keeps a Neutral rating on the shares following the Q3 report. The firm says PTC reported a strong first quarter of Sephience sales.
Barclays
Gena Wang
Equal Weight
maintain
$46 -> $68
2025-11-05
Reason
Barclays
Gena Wang
Price Target
$46 -> $68
2025-11-05
maintain
Equal Weight
Reason
Barclays analyst Gena Wang raised the firm's price target on PTC Therapeutics to $68 from $46 and keeps an Equal Weight rating on the shares following the earnings report.
See All Ratings

Valuation Metrics

The current forward P/E ratio for PTC Therapeutics Inc (PTCT.O) is -49.32, compared to its 5-year average forward P/E of -11.85. For a more detailed relative valuation and DCF analysis to assess PTC Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.85
Current PE
-49.32
Overvalued PE
-0.88
Undervalued PE
-22.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
19.89
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
214.22
Undervalued EV/EBITDA
-174.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.35
Current PS
0.00
Overvalued PS
5.80
Undervalued PS
2.90
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 3181.08% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PTCT News & Events

Events Timeline

(ET)
2025-12-01
10:00:00
Goldman Sachs Upgrades Chime to Buy with $27 Price Target
select
link
2025-12-01
09:10:00
Cadrenal Appoints PTC CMO Dr. Lee Scott Golden to Board of Directors
select
2025-12-01
06:22:00
RBC Downgrades PTC Therapeutics to Sector Perform with Price Target Raised to $91
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-02Newsfilter
PTC Therapeutics Grants Stock Options and RSUs to 15 New Employees
  • Employee Incentive Program: On November 24, 2025, PTC Therapeutics approved the grant of 2,000 stock options and 8,200 restricted stock units (RSUs) to 15 new employees, enhancing talent attraction and facilitating the company's recruitment efforts.
  • Stock Option Details: Each stock option has an exercise price of $79.83, based on the closing price on the grant date, with a 10-year term and a four-year vesting schedule designed to incentivize long-term employee retention and enhance company stability.
  • Restricted Stock Unit Arrangement: The RSUs will also vest over four years, with 25% of shares vesting on each annual anniversary of the employee's hire date, ensuring continued contributions during their tenure and fostering team cohesion.
  • Compliance and Strategic Significance: This grant complies with Nasdaq listing rules, reflecting PTC's commitment to talent and aiming to enhance employee satisfaction and overall company performance, supporting its long-term strategic goals in the biopharmaceutical sector.
[object Object]
Preview
5.0
12-02PRnewswire
PTC Therapeutics Grants Stock Options and RSUs to 15 New Employees
  • Employee Incentive Program: On November 24, 2025, PTC Therapeutics approved the grant of 2,000 stock options and 8,200 restricted stock units (RSUs) to 15 new employees, enhancing employee attraction and facilitating talent acquisition for the company.
  • Stock Option Details: Each stock option has an exercise price of $79.83, based on the closing price on the grant date, with a 10-year term and a four-year vesting schedule designed to incentivize long-term employee retention.
  • RSU Vesting Arrangement: The RSUs will vest over four years, with 25% of the shares vesting on each annual anniversary of the employee's hire date, ensuring continued contributions from employees during their tenure with the company.
  • Compliance and Strategic Significance: This grant complies with Nasdaq listing rules, reflecting PTC's commitment to talent and aiming to attract and retain key personnel through a competitive compensation structure to support the company's long-term growth in the biopharmaceutical sector.
[object Object]
Preview
6.0
12-01Benzinga
Amazon Set to Surge by 31%? Check Out 10 Leading Analyst Predictions for Monday

  • Analyst Upgrades and Downgrades: JP Morgan downgraded Argan Inc while raising its price target, Oppenheimer maintained an Outperform rating for Amazon with a price target increase, and RBC Capital downgraded PTC Therapeutics despite raising its price target.

  • Price Target Adjustments: Barclays lowered Crown Castle's price target and downgraded its rating, while Benchmark raised Light & Wonder's target and maintained a Buy rating.

  • Significant Increases: Mizuho raised Insmed's price target significantly and maintained an Outperform rating, while HSBC upgraded Thermo Fisher Scientific from Hold to Buy with a notable price target increase.

  • Mixed Ratings: Argus Research cut Target's price target but kept a Buy rating, and BMO Capital reduced Old Dominion's target while upgrading its rating to Outperform.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PTC Therapeutics Inc (PTCT) stock price today?

The current price of PTCT is 77.85 USD — it has increased 2.76 % in the last trading day.

arrow icon

What is PTC Therapeutics Inc (PTCT)'s business?

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

arrow icon

What is the price predicton of PTCT Stock?

Wall Street analysts forecast PTCT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTCT is 76.18 USD with a low forecast of 50.00 USD and a high forecast of 118.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PTC Therapeutics Inc (PTCT)'s revenue for the last quarter?

PTC Therapeutics Inc revenue for the last quarter amounts to 211.01M USD, increased 7.23 % YoY.

arrow icon

What is PTC Therapeutics Inc (PTCT)'s earnings per share (EPS) for the last quarter?

PTC Therapeutics Inc. EPS for the last quarter amounts to 0.18 USD, decreased -112.95 % YoY.

arrow icon

What changes have occurred in the market's expectations for PTC Therapeutics Inc (PTCT)'s fundamentals?

The market is revising No Change the revenue expectations for PTC Therapeutics, Inc. (PTCT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 35.96%.
arrow icon

How many employees does PTC Therapeutics Inc (PTCT). have?

PTC Therapeutics Inc (PTCT) has 939 emplpoyees as of December 05 2025.

arrow icon

What is PTC Therapeutics Inc (PTCT) market cap?

Today PTCT has the market capitalization of 6.25B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free